Last reviewed · How we verify
NCT06773455
Tralokinumab for Dupilumab Failures
Phase 4 trial testing tralokinumab in Atopic Dermatitis in 20 participants. Participants enrolled and being followed up; not accepting new ones.
1 February 2025
Quick facts
| Lead sponsor | Psoriasis Treatment Center of Central New Jersey |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 11 September 2023 |
| Primary completion | 1 February 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- tralokinumab (TRALOKINUMAB) — full drug profile →
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Psoriasis Treatment Center of Central New Jersey — full company profile →
Who can join
18 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06773455
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tralokinumab
Trials testing the same drug.
- NCT07444801 — Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact · recruiting
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Psoriasis Treatment Center of Central New Jersey trials
Trials by the same sponsor.
- NCT06103695 — Vtama in Psoriasis Patients Being Treated With Biologics. · Phase 4 · completed
- NCT06329258 — Combination of Sotyktu and Enstilar for Plaque Psoriasis · Phase 4 · completed
- NCT05285839 — Dupixent and Narrowband UVB for Atopic Dermatitis · Phase 4 · recruiting
- NCT04372277 — Taltz in Combination With Enstilar for Psoriasis · Phase 4 · recruiting
- NCT04347473 — ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis. · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06773455 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Psoriasis Treatment Center of Central New Jersey
- Last refreshed: 14 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06773455.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing